A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
Identifieur interne : 001B26 ( PubMed/Curation ); précédent : 001B25; suivant : 001B27A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
Auteurs : Xiaohua Wang [République populaire de Chine] ; Wei Xu ; Deyan Tong ; Jing Ni ; Haifeng Gao ; Ying Wang ; Yiwei Chu ; Pingping Li ; Xiaoming Yang ; Sidong XiongSource :
- Immunology letters [ 0165-2478 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Antigènes viraux (), Antigènes viraux (génétique), Antigènes viraux (immunologie), Clonage moléculaire, Déterminants antigéniques des lymphocytes B (), Déterminants antigéniques des lymphocytes B (génétique), Déterminants antigéniques des lymphocytes B (immunologie), Expression des gènes (génétique), Expression des gènes (immunologie), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Humains, Mémoire immunologique (génétique), Mémoire immunologique (immunologie), Production d'anticorps (génétique), Production d'anticorps (immunologie), Protéines de fusion recombinantes (génétique), Protéines de fusion recombinantes (immunologie), Protéines de fusion recombinantes (usage thérapeutique), Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines de la matrice virale (génétique), Protéines de la matrice virale (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (sang), Vaccins à ADN (), Vaccins à ADN (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
- MESH :
- génétique : Antigènes viraux, Déterminants antigéniques des lymphocytes B, Expression des gènes, Glycoprotéines membranaires, Mémoire immunologique, Production d'anticorps, Protéines de fusion recombinantes, Protéines de l'enveloppe virale, Protéines de la matrice virale, Syndrome respiratoire aigu sévère, Virus du SRAS.
- immunologie : Anticorps antiviraux, Antigènes viraux, Déterminants antigéniques des lymphocytes B, Expression des gènes, Glycoprotéines membranaires, Mémoire immunologique, Production d'anticorps, Protéines de fusion recombinantes, Protéines de l'enveloppe virale, Protéines de la matrice virale, Syndrome respiratoire aigu sévère, Vaccins à ADN, Virus du SRAS.
- pathogénicité : Virus du SRAS.
- sang : Anticorps antiviraux, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Protéines de fusion recombinantes.
- Animaux, Antigènes viraux, Clonage moléculaire, Déterminants antigéniques des lymphocytes B, Glycoprotéine de spicule des coronavirus, Humains, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Vaccins à ADN.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Formation (genetics), Antibody Formation (immunology), Antigens, Viral (chemistry), Antigens, Viral (genetics), Antigens, Viral (immunology), Cloning, Molecular, Epitopes, B-Lymphocyte (chemistry), Epitopes, B-Lymphocyte (genetics), Epitopes, B-Lymphocyte (immunology), Gene Expression (genetics), Gene Expression (immunology), Humans, Immunologic Memory (genetics), Immunologic Memory (immunology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), Recombinant Fusion Proteins (therapeutic use), SARS Virus (genetics), SARS Virus (immunology), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (blood), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, DNA (chemistry), Vaccines, DNA (immunology), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Matrix Proteins (genetics), Viral Matrix Proteins (immunology).
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , chemistry : Antigens, Viral, Epitopes, B-Lymphocyte, Vaccines, DNA.
- chemical , genetics : Antigens, Viral, Epitopes, B-Lymphocyte, Membrane Glycoproteins, Recombinant Fusion Proteins, Viral Envelope Proteins, Viral Matrix Proteins.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Epitopes, B-Lymphocyte, Membrane Glycoproteins, Recombinant Fusion Proteins, Vaccines, DNA, Viral Envelope Proteins, Viral Matrix Proteins.
- blood : Severe Acute Respiratory Syndrome.
- genetics : Antibody Formation, Gene Expression, Immunologic Memory, SARS Virus, Severe Acute Respiratory Syndrome.
- immunology : Antibody Formation, Gene Expression, Immunologic Memory, SARS Virus, Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- chemical , therapeutic use : Recombinant Fusion Proteins.
- Animals, Cloning, Molecular, Humans, Mice, Mice, Inbred BALB C, Spike Glycoprotein, Coronavirus.
Abstract
Epitope-based vaccines designed to induce antibody responses specific for severe acute respiratory syndrome-associated coronavirus (SARS-CoV) are being developed as a means for increasing vaccine potency. In this study, we identified four B cell epitopes from the spike (S) and membrane (M) protein through bioinformatics analysis and constructed a multi-epitope DNA vaccine. Intramuscular immunization of mice with this vaccine was sufficient to induce specific prime as well as a long-term memory humoral immune response to at least two candidate epitopes, S(437-459) and M(1-20). A DNA prime-protein boost strategy greatly enhanced the antibody generation and the immune sera not only reacted with the lysates of SARS-CoV-infected Vero cells but also neutralized the cytopathic effect of SARS by 75% at 1:160 dilution. The novel immunogenic S protein peptide revealed in this study provides new target for SARS vaccine design; and our work indicated multi-epitope DNA vaccine as an effective means for eliciting polyvalent humoral immune response against SARS-CoV.
DOI: 10.1016/j.imlet.2008.04.005
PubMed: 18533276
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B26
Links to Exploration step
pubmed:18533276Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.</title>
<author><name sortKey="Wang, Xiaohua" sort="Wang, Xiaohua" uniqKey="Wang X" first="Xiaohua" last="Wang">Xiaohua Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for ImmunoBiology, Department of Immunology, Shanghai Medical College of Fudan University, Shanghai 200032, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute for ImmunoBiology, Department of Immunology, Shanghai Medical College of Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Xu, Wei" sort="Xu, Wei" uniqKey="Xu W" first="Wei" last="Xu">Wei Xu</name>
</author>
<author><name sortKey="Tong, Deyan" sort="Tong, Deyan" uniqKey="Tong D" first="Deyan" last="Tong">Deyan Tong</name>
</author>
<author><name sortKey="Ni, Jing" sort="Ni, Jing" uniqKey="Ni J" first="Jing" last="Ni">Jing Ni</name>
</author>
<author><name sortKey="Gao, Haifeng" sort="Gao, Haifeng" uniqKey="Gao H" first="Haifeng" last="Gao">Haifeng Gao</name>
</author>
<author><name sortKey="Wang, Ying" sort="Wang, Ying" uniqKey="Wang Y" first="Ying" last="Wang">Ying Wang</name>
</author>
<author><name sortKey="Chu, Yiwei" sort="Chu, Yiwei" uniqKey="Chu Y" first="Yiwei" last="Chu">Yiwei Chu</name>
</author>
<author><name sortKey="Li, Pingping" sort="Li, Pingping" uniqKey="Li P" first="Pingping" last="Li">Pingping Li</name>
</author>
<author><name sortKey="Yang, Xiaoming" sort="Yang, Xiaoming" uniqKey="Yang X" first="Xiaoming" last="Yang">Xiaoming Yang</name>
</author>
<author><name sortKey="Xiong, Sidong" sort="Xiong, Sidong" uniqKey="Xiong S" first="Sidong" last="Xiong">Sidong Xiong</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18533276</idno>
<idno type="pmid">18533276</idno>
<idno type="doi">10.1016/j.imlet.2008.04.005</idno>
<idno type="wicri:Area/PubMed/Corpus">001B26</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B26</idno>
<idno type="wicri:Area/PubMed/Curation">001B26</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B26</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.</title>
<author><name sortKey="Wang, Xiaohua" sort="Wang, Xiaohua" uniqKey="Wang X" first="Xiaohua" last="Wang">Xiaohua Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for ImmunoBiology, Department of Immunology, Shanghai Medical College of Fudan University, Shanghai 200032, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute for ImmunoBiology, Department of Immunology, Shanghai Medical College of Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Xu, Wei" sort="Xu, Wei" uniqKey="Xu W" first="Wei" last="Xu">Wei Xu</name>
</author>
<author><name sortKey="Tong, Deyan" sort="Tong, Deyan" uniqKey="Tong D" first="Deyan" last="Tong">Deyan Tong</name>
</author>
<author><name sortKey="Ni, Jing" sort="Ni, Jing" uniqKey="Ni J" first="Jing" last="Ni">Jing Ni</name>
</author>
<author><name sortKey="Gao, Haifeng" sort="Gao, Haifeng" uniqKey="Gao H" first="Haifeng" last="Gao">Haifeng Gao</name>
</author>
<author><name sortKey="Wang, Ying" sort="Wang, Ying" uniqKey="Wang Y" first="Ying" last="Wang">Ying Wang</name>
</author>
<author><name sortKey="Chu, Yiwei" sort="Chu, Yiwei" uniqKey="Chu Y" first="Yiwei" last="Chu">Yiwei Chu</name>
</author>
<author><name sortKey="Li, Pingping" sort="Li, Pingping" uniqKey="Li P" first="Pingping" last="Li">Pingping Li</name>
</author>
<author><name sortKey="Yang, Xiaoming" sort="Yang, Xiaoming" uniqKey="Yang X" first="Xiaoming" last="Yang">Xiaoming Yang</name>
</author>
<author><name sortKey="Xiong, Sidong" sort="Xiong, Sidong" uniqKey="Xiong S" first="Sidong" last="Xiong">Sidong Xiong</name>
</author>
</analytic>
<series><title level="j">Immunology letters</title>
<idno type="ISSN">0165-2478</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibody Formation (genetics)</term>
<term>Antibody Formation (immunology)</term>
<term>Antigens, Viral (chemistry)</term>
<term>Antigens, Viral (genetics)</term>
<term>Antigens, Viral (immunology)</term>
<term>Cloning, Molecular</term>
<term>Epitopes, B-Lymphocyte (chemistry)</term>
<term>Epitopes, B-Lymphocyte (genetics)</term>
<term>Epitopes, B-Lymphocyte (immunology)</term>
<term>Gene Expression (genetics)</term>
<term>Gene Expression (immunology)</term>
<term>Humans</term>
<term>Immunologic Memory (genetics)</term>
<term>Immunologic Memory (immunology)</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Recombinant Fusion Proteins (genetics)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>Recombinant Fusion Proteins (therapeutic use)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Severe Acute Respiratory Syndrome (blood)</term>
<term>Severe Acute Respiratory Syndrome (genetics)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, DNA (chemistry)</term>
<term>Vaccines, DNA (immunology)</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Matrix Proteins (genetics)</term>
<term>Viral Matrix Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Antigènes viraux ()</term>
<term>Antigènes viraux (génétique)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Clonage moléculaire</term>
<term>Déterminants antigéniques des lymphocytes B ()</term>
<term>Déterminants antigéniques des lymphocytes B (génétique)</term>
<term>Déterminants antigéniques des lymphocytes B (immunologie)</term>
<term>Expression des gènes (génétique)</term>
<term>Expression des gènes (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Mémoire immunologique (génétique)</term>
<term>Mémoire immunologique (immunologie)</term>
<term>Production d'anticorps (génétique)</term>
<term>Production d'anticorps (immunologie)</term>
<term>Protéines de fusion recombinantes (génétique)</term>
<term>Protéines de fusion recombinantes (immunologie)</term>
<term>Protéines de fusion recombinantes (usage thérapeutique)</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Protéines de la matrice virale (génétique)</term>
<term>Protéines de la matrice virale (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (génétique)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (sang)</term>
<term>Vaccins à ADN ()</term>
<term>Vaccins à ADN (immunologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antigens, Viral</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Vaccines, DNA</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Membrane Glycoproteins</term>
<term>Recombinant Fusion Proteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Membrane Glycoproteins</term>
<term>Recombinant Fusion Proteins</term>
<term>Vaccines, DNA</term>
<term>Viral Envelope Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Antibody Formation</term>
<term>Gene Expression</term>
<term>Immunologic Memory</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term>
<term>Déterminants antigéniques des lymphocytes B</term>
<term>Expression des gènes</term>
<term>Glycoprotéines membranaires</term>
<term>Mémoire immunologique</term>
<term>Production d'anticorps</term>
<term>Protéines de fusion recombinantes</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines de la matrice virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Antigènes viraux</term>
<term>Déterminants antigéniques des lymphocytes B</term>
<term>Expression des gènes</term>
<term>Glycoprotéines membranaires</term>
<term>Mémoire immunologique</term>
<term>Production d'anticorps</term>
<term>Protéines de fusion recombinantes</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines de la matrice virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins à ADN</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Formation</term>
<term>Gene Expression</term>
<term>Immunologic Memory</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protéines de fusion recombinantes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cloning, Molecular</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Antigènes viraux</term>
<term>Clonage moléculaire</term>
<term>Déterminants antigéniques des lymphocytes B</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins à ADN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Epitope-based vaccines designed to induce antibody responses specific for severe acute respiratory syndrome-associated coronavirus (SARS-CoV) are being developed as a means for increasing vaccine potency. In this study, we identified four B cell epitopes from the spike (S) and membrane (M) protein through bioinformatics analysis and constructed a multi-epitope DNA vaccine. Intramuscular immunization of mice with this vaccine was sufficient to induce specific prime as well as a long-term memory humoral immune response to at least two candidate epitopes, S(437-459) and M(1-20). A DNA prime-protein boost strategy greatly enhanced the antibody generation and the immune sera not only reacted with the lysates of SARS-CoV-infected Vero cells but also neutralized the cytopathic effect of SARS by 75% at 1:160 dilution. The novel immunogenic S protein peptide revealed in this study provides new target for SARS vaccine design; and our work indicated multi-epitope DNA vaccine as an effective means for eliciting polyvalent humoral immune response against SARS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18533276</PMID>
<DateCompleted><Year>2009</Year>
<Month>02</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-2478</ISSN>
<JournalIssue CitedMedium="Print"><Volume>119</Volume>
<Issue>1-2</Issue>
<PubDate><Year>2008</Year>
<Month>Aug</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Immunology letters</Title>
<ISOAbbreviation>Immunol. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.</ArticleTitle>
<Pagination><MedlinePgn>71-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imlet.2008.04.005</ELocationID>
<Abstract><AbstractText>Epitope-based vaccines designed to induce antibody responses specific for severe acute respiratory syndrome-associated coronavirus (SARS-CoV) are being developed as a means for increasing vaccine potency. In this study, we identified four B cell epitopes from the spike (S) and membrane (M) protein through bioinformatics analysis and constructed a multi-epitope DNA vaccine. Intramuscular immunization of mice with this vaccine was sufficient to induce specific prime as well as a long-term memory humoral immune response to at least two candidate epitopes, S(437-459) and M(1-20). A DNA prime-protein boost strategy greatly enhanced the antibody generation and the immune sera not only reacted with the lysates of SARS-CoV-infected Vero cells but also neutralized the cytopathic effect of SARS by 75% at 1:160 dilution. The novel immunogenic S protein peptide revealed in this study provides new target for SARS vaccine design; and our work indicated multi-epitope DNA vaccine as an effective means for eliciting polyvalent humoral immune response against SARS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Xiaohua</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Institute for ImmunoBiology, Department of Immunology, Shanghai Medical College of Fudan University, Shanghai 200032, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tong</LastName>
<ForeName>Deyan</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ni</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Haifeng</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chu</LastName>
<ForeName>Yiwei</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Pingping</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Xiaoming</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xiong</LastName>
<ForeName>Sidong</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>05</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Immunol Lett</MedlineTA>
<NlmUniqueID>7910006</NlmUniqueID>
<ISSNLinking>0165-2478</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>108502-71-2</RegistryNumber>
<NameOfSubstance UI="C067997">M protein, Coronavirus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>02</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>04</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>04</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18533276</ArticleId>
<ArticleId IdType="pii">S0165-2478(08)00119-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.imlet.2008.04.005</ArticleId>
<ArticleId IdType="pmc">PMC7112888</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6352-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9177221</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16339739</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunity. 2004 Nov;21(5):617-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15539149</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Mol Immunol. 2005 Apr;2(2):101-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16191415</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Mol Genet. 1992 Sep;1(6):363-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1301910</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2007 Mar 15;359(2):264-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17055022</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13263-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11069289</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2003 Nov 15;171(10):5611-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14607970</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Jan;82(1):435-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17942551</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>DNA Cell Biol. 2005 Aug;24(8):503-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16101348</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2006 Feb 6;580(3):968-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16442106</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2000 May;74(10):4839-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10775623</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2005 Aug;43(8):3718-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081901</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2005 Oct;77(2):147-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16121363</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biomed Environ Sci. 2005 Dec;18(6):363-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16544518</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Feb;69(2):70-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16337697</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Feb 20;26(8):1098-110</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18243434</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol Methods. 1998 Jun;72(2):145-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9694322</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2008 Feb;89(Pt 2):453-466</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18198376</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Immunol. 2003 Aug;15(4):461-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12900280</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Immunol. 2004 Feb;25(2):98-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15102369</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):255-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780875</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 2;319(3):929-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15184071</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:18533276 |texte= A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18533276" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |